Based on the fifth edition of the World Health Organization (WHO) classification of the central nervous system tumors [3], histological classification and molecular biomarkers, such as grade I to IV, isocitrate dehydrogenase 1 and 2 (IDH1/IDH2)mutation and chromosome 1p/19q co-deletion status, have been used in diagnosis, treatment and prognostic evaluation of glioma [4]. This evidence concerns the gene IDH1 and central nervous system cancer.